Table 2.
Demographic and clinical characteristics of the study population and distribution of scores for each questionnaire (n=159)
| Demographic and clinical variables | Mean | SD | Median | IQR |
|---|---|---|---|---|
| Age (years) | 56.49 | 11.65 | 56.00 | 49.00–65.00 |
| Educational level (years) | 11.07 | 3.27 | 13.00 | 8.00–13.00 |
| Disease duration (years) | 8.40 | 5.21 | 8.00 | 3.00–12.00 |
| Number of comorbidities | 2.57 | 1.92 | 2.00 | 1.00–4.00 |
| SCQ (range 0–39) | 4.75 | 3.60 | 4.65 | 1.45–7.00 |
| TJC (68 joints) | 5.99 | 5.96 | 4.00 | 0.00–11.00 |
| SJC (66 joints) | 3.78 | 4.05 | 4.00 | 0.00–6.00 |
| ESR (mm/h) | 25.15 | 17.99 | 22.00 | 11.20–34.00 |
| CRP (mg/dL) | 3.56 | 3.37 | 2.22 | 1.02–5.51 |
| Pain (range 0–10) | 4.44 | 2.69 | 5.00 | 2.00–6.00 |
| Dactylitis count (range 0–20) | 2.01 | 2.28 | 1.00 | 0.00–4.00 |
| LEI (range 0–6) | 1.39 | 3.36 | 1.00 | 0.00–2.00 |
| PASDAS (range 0–10) | 4.44 | 1.77 | 5.00 | 2.98–5.74 |
| DAPSA (range 0–164) | 21.76 | 14.44 | 25.00 | 7.00–32.12 |
| PASI (range 0–72) | 5.36 | 5.08 | 4.40 | 1.12–8.47 |
| PhGA (range 0–10) | 3.98 | 2.70 | 5.00 | 1.00–6.00 |
| HAQ (range 0–3) | 1.07 | 0.70 | 1.12 | 0.50–1.62 |
| SF-36 PCS (range 0–100) | 38.87 | 10.32 | 36.29 | 31.63–46.61 |
| SF-36 MCS (range 0–100) | 44.29 | 12.26 | 42.22 | 33.4–54.58 |
Abbreviations: SD, standard deviation; IQR, interquartile range; SCQ, Self-administered Comorbidity Questionnaire; TJC, tender joint count; SJC, swollen joint count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; LEI, Leeds Enthesitis Index; PASDAS, Psoriatic Arthritis Disease Activity Score; DAPSA, Disease Activity Index for Psoriatic Arthritis; PASI, Psoriasis Area and Severity Index; PhGA, Physician Assessment of disease activity; HAQ, Health Assessment Questionnaire; SF-36 PCS, Physical Component Summary score of the Medical Outcome Survey Short Form-36; SF-36 MCS, Mental Component Summary score of the Medical Outcome Survey Short Form-36.